<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711919</url>
  </required_header>
  <id_info>
    <org_study_id>C-255</org_study_id>
    <secondary_id>UMIN000001229</secondary_id>
    <nct_id>NCT00711919</nct_id>
  </id_info>
  <brief_title>Pitavastatin on Carotid Intima-media Thickness</brief_title>
  <acronym>PEACE</acronym>
  <official_title>Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto Prefectural University of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto Prefectural University of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to analyze the effects of aggressive and conventional lipid lowering
      therapy with Pravastatin on carotid intima-media thickness (IMT) in patients with
      hyperlipidemia and abnormal thickening of IMT.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>absolute changes in carotid intima-media thickness from baseline to final visit</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>relative change in carotid intima-media thickness</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in LDL-C, HDL-C, TG and RLP-C</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in hs-CRP and IL-6</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new onset or recurrence of ischemic heart disease, heart failure, stroke and atherosclerosis obliterans</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sudden death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Carotid Artery Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months. After administration, serum LDL-cholesterol should be kept between 100 and 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months. After administration, serum LDL-cholesterol should be kept under 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>comparison of different target levels of lipid lowering using Pitavastatin
Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as having hyperlipidemia

          -  LDL-C at the time of enrollment is no less than 100

          -  Common carotid IMT is 1.1 mm and over

        Exclusion Criteria:

          -  Received or planned to receive intervention on carotid arteries during the study
             period

          -  Overt liver dysfunction (ALT; 100 IU/L and over)

          -  Overt renal dysfunction (serum creatinine; 2.0 mg/dL and over)

          -  Receiving Cyclosporin

          -  Hyperreactive to Pitavastatin

          -  During pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Matsubara, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kyoto Prefectural University of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ayabe City Hospital</name>
      <address>
        <city>Ayabe</city>
        <state>Kyoto</state>
        <zip>623-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuchiyama City Hospital</name>
      <address>
        <city>Fukuchiyama</city>
        <state>Kyoto</state>
        <zip>620‚Äê8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanabe Central Hospital</name>
      <address>
        <city>Kyotanabe</city>
        <state>Kyoto</state>
        <zip>610-0334</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumihama Hospital</name>
      <address>
        <city>Kyotango</city>
        <state>Kyoto</state>
        <zip>629-3400</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maizuru Medical Center</name>
      <address>
        <city>Maizuru</city>
        <state>Kyoto</state>
        <zip>625-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maizuru Kyosai Hospital</name>
      <address>
        <city>Maizuru</city>
        <state>Kyoto</state>
        <zip>625-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kyoto Hospital</name>
      <address>
        <city>Nagaokakyo</city>
        <state>Kyoto</state>
        <zip>617-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantan General Hospital</name>
      <address>
        <city>Nantan</city>
        <state>Kyoto</state>
        <zip>629-0197</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meiji University of Integrative Medicine Hospital</name>
      <address>
        <city>Nantan</city>
        <state>Kyoto</state>
        <zip>629-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gakken Toshi Hospital</name>
      <address>
        <city>Seika</city>
        <state>Kyoto</state>
        <zip>619-0238</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uji Hospital</name>
      <address>
        <city>Uji</city>
        <state>Kyoto</state>
        <zip>611-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural Yosanoumi Hospital</name>
      <address>
        <city>Yosano</city>
        <state>Kyoto</state>
        <zip>629-2261</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga Hospital</name>
      <address>
        <city>Higashioumi</city>
        <state>Shiga</state>
        <zip>527-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omihachiman Community Medical Center</name>
      <address>
        <city>Omihachiman</city>
        <state>Shiga</state>
        <zip>523-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Shigaken Hospital</name>
      <address>
        <city>Rittou</city>
        <state>Shiga</state>
        <zip>520-3046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takeda Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>600-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto First Red Cross Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>605-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hiroaki Matsubara</name_title>
    <organization>Kyoto Prefectural University of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

